Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019

por Aroldi, Andrea, Chiarle, Roberto, Gambacorti-Passerini, Carlo
Publicado 2021

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia

por Fontana, Diletta, Gambacorti-Passerini, Carlo, Piazza, Rocco
Publicado 2021

Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells

por Mologni, Luca, Brussolo, Stefania, Ceccon, Monica, Gambacorti-Passerini, Carlo
Publicado 2012

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK

por Fontana, Diletta, Ceccon, Monica, Gambacorti-Passerini, Carlo, Mologni, Luca
Publicado 2015

Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success

por Inzoli, Elena, Aroldi, Andrea, Piazza, Rocco, Gambacorti‐Passerini, Carlo
Publicado 2022

The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhib...

por Mologni, Luca, Magistroni, Vera, Casuscelli, Francesco, Montemartini, Marisa, Gambacorti-Passerini, Carlo
Publicado 2017

PB2182: NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) AT DIAGNOSIS IN ESSENTIAL THROMBOCYTEMIA (ET): A NEW PREDICTOR OF THROMBOTIC EVENTS

por Ripamonti, Alessia, Cavalca, Fabrizio, Agostani, Elena, Gambacorti-Passerini, Carlo, Elli, Elena Maria
Publicado 2023

Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea

por Renso, Rossella, Aroldi, Andrea, Pioltelli, Pietro, Gambacorti-Passerini, Carlo, Elli, Elena Maria
Publicado 2018

Locking Src/Abl Tyrosine Kinase Activities Regulate Cell Differentiation and Invasion of Human Cervical Cancer Cells Expressing E6/E7 Oncoproteins of High-Risk HPV

por Yasmeen, Amber, Alachkar, Amal, Dekhil, Hafedh, Gambacorti-Passerini, Carlo, Al Moustafa, Ala-Eddin
Publicado 2010

An Imatinib–non‐responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization

por Crespiatico, Ilaria, Bossi, Elisa, Brioschi, Filippo, Piazza, Rocco, Mologni, Luca, Gambacorti‐Passerini, Carlo
Publicado 2019

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes

por Sharma, Geeta Geeta, Mota, Ines, Mologni, Luca, Patrucco, Enrico, Gambacorti-Passerini, Carlo, Chiarle, Roberto
Publicado 2018

Being a Myeloproliferative Patient in COVID-19 Era: The Mytico Study

por Cavalca, Fabrizio, Renso, Rossella, Zambrotta, Giovanni Paolo Maria, Gambacorti-Passerini, Carlo, Elli, Elena Maria
Publicado 2021

Single‐center study on SARS‐CoV‐2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization

por Civettini, Ivan, Antolini, Laura, Brioschi, Filippo, Zambrotta, Giovanni Paolo Maria, Guglielmana, Veronica, Gambacorti‐Passerini, Carlo
Publicado 2023

FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery

por Piazza, Rocco, Pirola, Alessandra, Spinelli, Roberta, Valletta, Simona, Redaelli, Sara, Magistroni, Vera, Gambacorti-Passerini, Carlo
Publicado 2012

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922

por Mologni, Luca, Ceccon, Monica, Pirola, Alessandra, Chiriano, Gianpaolo, Piazza, Rocco, Scapozza, Leonardo, Gambacorti-Passerini, Carlo
Publicado 2015

Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling

por Ceccon, Monica, Mauri, Mario, Massimino, Luca, Giudici, Giovanni, Piazza, Rocco, Gambacorti-Passerini, Carlo, Mologni, Luca
Publicado 2018

VERSO: A comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples

por Ramazzotti, Daniele, Angaroni, Fabrizio, Maspero, Davide, Gambacorti-Passerini, Carlo, Antoniotti, Marco, Graudenzi, Alex, Piazza, Rocco
Publicado 2021

PB1976: SINGLE CENTER STUDY ON SARS-COV-2 INFECTION IN PATIENTS AFFECTED BY CML: VACCINATION STATUS AND BOSUTINIB THERAPY AS POSSIBLE PROTECTIVE FACTORS FOR HOSPITALIZATION.

por Civettini, Ivan, Antolinni, Laura, Brioschi, Filippo Achille, Zambrotta, Giovanni Paolo Maria, Guglielmana, Veronica, Gambacorti-Passerini, Carlo
Publicado 2023

Pregnancy outcomes in patients treated with bosutinib

por Cortes, Jorge E, Gambacorti-Passerini, Carlo, Deininger, Michael, Abruzzese, Elisabetta, DeAnnuntis, Liza, Brümmendorf, Tim H
Publicado 2020

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene

por Sharma, Nitesh, Magistroni, Vera, Piazza, Rocco, Citterio, Stefania, Mezzatesta, Caterina, Khandelwal, Praveen, Pirola, Alessandra, Gambacorti-Passerini, Carlo
Publicado 2015